IRRAS (DB:4Z7) - Aandelenkoers, Nieuws & Analyse

4Z7 Overzicht aandelen

IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide.

Over het bedrijf

4Z7 fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Revenue is forecast to grow 84.69% per year

Risicoanalyse

Shares are highly illiquid

Has less than 1 year of cash runway

Does not have meaningful revenue (SEK43M)

Shareholders have been diluted in the past year

+ 1 meer risico

IRRAS AB (publ) Concurrenten

PULSION Medical Systems

MUN:PUS

€127.8m

Stratec

XTRA:SBS

€413.9m

Eckert & Ziegler

XTRA:EUZ

€814.6m

Drägerwerk KGaA

XTRA:DRW3

€810.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor IRRAS
Historische aandelenkoersen
Huidige aandelenkoers	US$0.013
52 Week Hoogtepunt	US$0.041
52 Week Laag	US$0.01
Bèta	0
11 maand verandering	0%
3 maanden verandering	3.15%
1 Jaar Verandering	-66.41%
33 jaar verandering	-98.10%
5 jaar verandering	n/a
Verandering sinds IPO	-97.88%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	4Z7	DE Medical Equipment	DE Markt
7D	0%	-2.7%	-1.8%
1Y	-66.4%	-2.7%	13.6%

Rendement versus industrie: 4Z7 underperformed the German Medical Equipment industry which returned -0% over the past year.

Rendement versus markt: 4Z7 underperformed the German Market which returned 0.4% over the past year.

Prijsvolatiliteit

Is 4Z7's price volatile compared to industry and market?
4Z7 volatility
4Z7 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.3%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.5%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: 4Z7 has not had significant price volatility in the past 3 months.

Volatiliteit in de loop van de tijd: Insufficient data to determine 4Z7's volatility change over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2011	47	Will Martin	www.irras.com

IRRAS AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van IRRAS zich tot de beurswaarde?
4Z7 fundamentele statistieken
Marktkapitalisatie	€167.97m
Inkomsten(TTM)	-€196.40m
Inkomsten(TTM)	€43.10m

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is 4Z7 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
4Z7 resultatenrekening (TTM)
Inkomsten	SEK 43.10m
Kosten van inkomsten	SEK 44.03m
Brutowinst	-SEK 935.00k
Overige uitgaven	SEK 195.47m
Inkomsten	-SEK 196.40m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

Feb 21, 2024

Winst per aandeel (EPS)	-0.17
Brutomarge	-2.17%
Nettowinstmarge	-455.71%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 4Z7 op de lange termijn?

Bekijk historische prestaties en vergelijking

4Z7 Overzicht aandelen

Beloningen

Risicoanalyse

IRRAS AB (publ) Concurrenten

MUN:PUS

€127.8m

XTRA:SBS

€413.9m

XTRA:EUZ

€814.6m

XTRA:DRW3

€810.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

Recent updates

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

IRRAS AB (Publ) Announces Resignation of Eva Nilsagård as a Board Member

First quarter 2023 earnings released: kr0.07 loss per share (vs kr0.42 loss in 1Q 2022)

Insufficient new directors

Insufficient new directors

Full year 2022 earnings released: kr0.52 loss per share (vs kr1.89 loss in FY 2021)

IRRAS AB (publ) Announces That the Publication of the First Comparative Study

IRRAS AB (publ) to Report Q4, 2023 Results on Feb 21, 2024

Insufficient new directors

IRRAS Receives US FDA 510(K) Clearance for Its Next Generation IRRAflow Control Unit

Insufficient new directors

IRRAS AB (publ) SHARE AK to Be Deleted from OTC Equity

IRRAS AB (publ) to Report Q4, 2022 Results on Feb 22, 2023

Insufficient new directors

IRRAS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 214.599618 million.

Irras Announces First Patient Treatments At Mount Sinai Health System in New York as Part of the Dive Study

Second quarter 2022 earnings released: kr0.46 loss per share (vs kr0.40 loss in 2Q 2021)

IRRAS AB Provides Revenue Guidance for the Year 2022

Insufficient new directors

IRRAS AB (publ) Announces First Global Patient Treatment with Next-Generation IRRAflow® System

IRRAS AB (publ) Launches Next-Generation of the IRRAflow System in the United States

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

IRRAS AB (publ) to Report Q2, 2022 Results on Jul 22, 2022

IRRAS Announces Presentation of the Dataset to Date to Document Clinical Outcomes Using Its IRRAflow system

IRRAS Announces First Patients Enrolled in ACTIVE Study, a Comparative Clinical Trial Designed to Confirm IRRAflow's Efficacy to Traditional Passive Drainage

Third quarter 2021 earnings released: kr0.34 loss per share (vs kr0.47 loss in 3Q 2020)

IRRAS AB (publ) Demonstrates Ability to Treat Pyogenic Ventriculitis Through Targeted Delivery of Antibiotics in Case Series Published in Neurosurgery Open

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.55 loss in 2Q 2020)

IRRAS AB Receives Extension of Its MDSAP Certification and Scope Expansion of MDSAP & ISO 13485:2016 Certifications

IRRAS AB Announces Publication of A Case Report from Buffalo General Medical Center, Highlights Clinical Superiority of IRRAflow Treatment Versus Traditional Drainage

First quarter 2021 earnings released: kr0.58 loss per share (vs kr1.19 loss in 1Q 2020)

Irras Announces the Recruitment of Sten Gustafsson as Director of Investor Relations

New 90-day low: €0.62

Full year 2020 earnings released: kr24.64 loss per share (vs kr5.61 loss in FY 2019)

Revenue misses expectations

Irras AB Announces an Exclusive Distribution Agreement with Medical Innovation Solutions

IRRAS AB Announces Exclusive Distribution Agreement with Anade SA

New 90-day high: €0.81

IRRAS AB Announces an Exclusive Distribution Agreement with KM Innovations BV

IRRAS AB Announces Breakthrough Technology Purchasing Agreement with Premier for Hummingbird ICP Monitoring Products

Revenue misses expectations

Third quarter 2020 earnings released: kr0.47 loss per share

New 90-day high: €0.66

First half earnings released

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

IRRAS AB (publ) Samenvatting

0.0x

0.0x

Inkomsten en omzet